Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
31.60
-0.96 (-2.95%)
At close: Mar 28, 2025, 4:00 PM
31.71
+0.11 (0.34%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Avidity Biosciences Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Avidity Biosciences stock have an average target of 68.25, with a low estimate of 53 and a high estimate of 96. The average target predicts an increase of 115.98% from the current stock price of 31.60.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Avidity Biosciences stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Buy | 4 | 5 | 5 | 4 | 4 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 11 | 10 | 10 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +127.85% | Mar 18, 2025 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +89.87% | Mar 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +127.85% | Mar 17, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $65 | Strong Buy | Maintains | $65 | +105.70% | Mar 17, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $70 | Strong Buy | Initiates | $70 | +121.52% | Mar 13, 2025 |
Financial Forecast
Revenue This Year
6.60M
from 10.90M
Decreased by -39.48%
Revenue Next Year
21.77M
from 6.60M
Increased by 230.08%
EPS This Year
-3.34
from -2.89
EPS Next Year
-3.66
from -3.34
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 22.1M | 81.6M | 675.2M | ||
| Avg | 6.6M | 21.8M | 348.5M | ||
| Low | n/a | n/a | 78.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 102.3% | 1,137.1% | 3,001.4% | ||
| Avg | -39.5% | 230.1% | 1,500.8% | ||
| Low | - | - | 260.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.60 | -2.37 | 1.17 | ||
| Avg | -3.34 | -3.66 | -0.90 | ||
| Low | -4.45 | -4.72 | -3.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.